Pitolisant GR

Small molecule

Filedunder review

Evidence outlook · regulatory review

Narcolepsy: application under FDA review, decision date 2027-04-01

PDUFA date for the Pitolisant GR NDA (2027-04-01). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

Other Histamine H3 receptor (antagonist / inverse agonist) drugs

Pitolisant (Wakix), ALTO-203. Compare all 3 Histamine H3 receptor (antagonist / inverse agonist) drugs

2 other tracked programmes target this mechanism.

This drug's own stage for Narcolepsy: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pitolisant GR: this drugStage not on recordSmall moleculeHistamine H3 receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav)ApprovedSmall moleculeGABA-B receptornot yet gradedNo reviewed efficacy summary in this indication
Modafinil (Provigil)ApprovedSmall moleculeSympathomimetic-like Agentnot yet gradedNo reviewed efficacy summary in this indication
Oveporexton (Orzeyful)ApprovedSmall moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Pitolisant (Wakix)ApprovedSmall moleculeHistamine H3 receptor (antagonist / inverse agonist)Reliable signal
NCT02611687: To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): Pitolisant -6.29 score on a scale (Standard Error 1.14) | Placebo -2.6 score on a scale (Standard Error 1.35)
Sodium OxybateApprovedSmall moleculeGABA-B receptorPartial signalFeatured results are non-efficacy only in this race
Solriamfetol (Sunosi)ApprovedSmall moleculeDopamine/norepinephrine transporterPartial signal
NCT02348632: Change in Epworth Sleepiness Scale score from the start to the end of the 2-week randomized-withdrawal period (positive = worse): +1.6 with continued solriamfetol (n=139) vs +5.3 after switch to placebo (n=141); difference -3.7 points (95% CI -4.8 to -2.7), significant after multiplicity adjustment (SUNOSI label Table 8; CT.gov posted results).
NCT02348593: Change from baseline to week 12 vs placebo: MWT +12.3 (300 mg) and +9.8 (150 mg) vs +2.1 minutes; ESS -6.4 and -5.4 vs -1.6 points (all p<0.0001). The 75 mg dose (MWT +4.74, ESS -3.8) was not statistically significant on either coprimary (Thorpy et al., Ann Neurol 2019; SUNOSI label).
AlixorextonPhase 3Small moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
ReboxetinePhase 3Small moleculenorepinephrine transporterPartial signal
NCT05113745: Primary endpoint, change in frequency of cataplexy attacks in the randomized withdrawal phase: statistically significant improvement vs placebo (Axsome, 2024-11-26).
CleminorextonPhase 2/3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
TAK-360Phase 2/3Small moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
ALTO-203
Phase 2(overall)
Small moleculeHistamine H3 receptor (antagonist / inverse agonist)
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

1 April 2027FDA action datePDUFA date for the Pitolisant GR NDA
US, FDA · Source ↗

Recent

4 November 2026Filing acceptedFDA accepts NDA for Pitolisant GR
US, FDA · Source ↗